Pharmacokinetics of Certoparin in Subjects With Renal Insufficiency and Healthy Subjects

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the pharmacokinetics in subjects with severe renal insufficiency and healthy subjects.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Certoparin; Dihydroergotamine; Heparin, Low-Molecular-Weight

Criteria

Inclusion criteria:

• Healthy subjects OR

• Subjects with severe renal insufficiency

Exclusion criteria:

• Hypersensitivity to study medication

• Genetic abnormality or disease of clotting system

• Prior major surgery or bleeding

• Other protocol-defined inclusion/exclusion criteria may apply